Background: The psoriasis xenograft severe combined immuno-deficiency (SCID) mouse model is used in drug discovery to obtain preclinical proof-of-principle of new anti-psoriatic drug candidates. Validation of this model by anti-psoriatic therapeutic agents in clinical use is important to understand its utility as well as its limitations. The effects of the clinically efficacious anti-TNFα biologics have not yet been demonstrated in the psoriasis xenograft SCID mouse model.
Objectives: To investigate the effect of etanercept and to explore the time-dependent changes induced by CsA on psoriatic biomarkers at the gene expression level in ...
Translating clinical activity and gene expression signatures of etanercept and cyclosporine A to the psoriasis xenograft SCID mouse model is a post from: Skincare
Translating clinical activity and gene expression signatures of etanercept and cyclosporine A to the psoriasis xenograft SCID mouse model via BuzzBlazer.com
No comments:
Post a Comment